SYNTHETECH - NZYM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SYNTHETECH - NZYM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (352)	5/15/2001 7:34:02 PM
From: Dan Gibbs	Read Replies (3) of 372

There have been a couple of recent news items about peptide-based drugs. Today, Bistol-Myers announced that a repeat trial of Vanlev will be complete "around late summer or early fall." Vanlev is a peptide-like small molecule antihypertensive that was yanked when cases of laryngeal edema were associated with its use. I think they are using a different dose in the current trial. If the drug turns out to be safe and effective and is approved by the FDA, it may be a blockbuster as it has an impressive ability to lower diastolic blood pressure, unlike most other drugs. I think it is possible if not likely that NZYM will be supplying PBBs for Vanlev. The other new drug is Angiomax, a 20 aminoacid peptide thrombin inhibitor used during coronary angioplasty. This was just recently approved, but is in a competitive market with ReoPro, Integrilin, and Aggrastat. Angiomax started life as Biogen's Hirulog. Biogen gave up when some of the trials weren't as impressive as they had hoped and sold the drug. I don't know who is supplying the amino acid PBBs for the synthesis of Angiomax. If not NZYM, it is one of its competitors.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next